Will Kyle Bass’s Drug Patent Gambit Pay Off? He’ll Soon Find Out

Hedge-fund manager Kyle Bass has been accusing drugmakers all year of misusing patents to reap “monopoly profits” for medicines, saying he wants to cash in by getting their patents tossed.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.